CEGID
13.6.2022 16:02:10 CEST | Business Wire | Press release
Cegid, a leading provider of cloud business management solutions for finance (treasury, tax, ERP), human resources (payroll, talent management), CPAs, retail and entrepreneurial sectors announces the acquisition of StorIQ, a London-based company with a staff of about thirty founded in 2015. The StorIQ in-store activity management platform is a valuable addition to Cegid’s retail portfolio, thereby bolstering its position as leader in retail POS solutions in France and worldwide.
StorIQ is particularly suitable for retailers with between 50 and 2,000 stores and already boasts around fifty clients including top brands such as Hugo Boss, Clarks, Douglas, Marks & Spencer International, Mountain Warehouse and Nespresso, some of which have deployed its solutions across the globe. StorIQ currently supports over 11,000 stores in more than 50 countries.
The StorIQ platform streamlines store activity planning and boosts productivity. The solution includes several modules:
- Task management and store communication: clear communication and prioritised tasks enable store managers to deliver brand standards and the expected in-store customer experience;
- Compliance: store visit reports, checklists, photo consolidation and associated reporting gives retail management teams real time visibility into store standards;
- Team Engagement: mobile learning (LMS), knowledge base and newsfeeds build employee engagement and support retention;
- Activity Planning: streamlines planning and communication for trading events and other in-store operational activity.
With 1,000 retailers running Cegid retail solutions in 75 countries, i.e. 75,000 connected stores, Cegid is helping speciality retailers and luxury brands transition to digital so as to better manage their omnichannel retail business, never miss a sale and tap into customer potential. The Cegid Retail unified commerce platform makes it possible to deliver an outstanding tailor-made shopping experience in stores worldwide. Thanks to StorIQ, the platform will now be able to cover all aspects of POS management.
StorIQ is an innovative solution built specifically for retail, and this acquisition cements Cegid’s expertise in all aspects of store operations - and further consolidates its international footprint. In addition, by improving employee experience in specialist retail, Cegid is securing its leadership in talent management.
“More than ever, the future of bricks-and-mortar stores will depend on the ability of retailers to accelerate and adapt so as to offer outstanding customer experiences as well as innovative and convenient services - while simplifying and monitoring in-store team task management. By capitalising on the current offerings of Cegid and StorIQ, brands and retailers will be able to offer an exceptional unified shopping experience across their entire store network while tapping into new sales opportunities ,” explains Cegid CEO Pascal Houillon. “Our current and future customers will be able to benefit from the optimised POS activity management offered by StorIQ paving their way to success . That’s what Retail the New Way is all about.”
StorIQ co-founder and Managing Director Amy Bastow and all the company staff will be joining the Cegid Retail Business Unit headed by Nathalie Echinard.
About StorIQ
StorIQ is a neat and intuitive retail operations app that saves time and makes life easier for store teams and retail management teams. StorIQ streamlines communications and task management, helping store teams to deliver brilliant brand standards, and retail leaders to make sure their stores get every detail right every day – maximising the value of the store estate. StorIQ is the easiest retail operations app to implement, with the most retail-specific feature set, and a world-class aftercare programme that ensures StorIQ delivers outstanding long term engagement.
StorIQ supports 11,000 stores in 55 countries, and our customers include global brands and local specialists across all sectors.
Founded in 2015, the company has around 30 employees and is based in London.
For more information: https://www.storiq.net/
About Cegid
Cegid is a leading provider of cloud business management solutions for finance (treasury, tax, ERP), human resources (payroll, talent management), CPAs, retail and entrepreneurial sectors. With a solid full cloud business model, Cegid provides long term commitment to its customers, superior and distinctive experiences and helps companies of all sizes accelerate their digital business transformation, locally and worldwide. Cegid combines a forward looking and pragmatic approach of the business with strong capacity to innovate, an in-depth expertise in new technologies and a unique understanding of regulations and compliance. In today’s rapidly changing world, Cegid makes more possible by helping customers unleash their potential thanks to innovative and purposeful business solutions.
Bolstered by its strong international ambition and reach, Cegid has 3,600 employees and sells its solutions in 130 countries. Cegid reported annual revenues of €632 million (December 31 2021). Pascal Houillon has been the CEO since March 2017.
For more information: www.cegid.com/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005087/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
